Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study

被引：2

作者：

Strati, Paolo ^{[1
]}

Champion, Rebecca ^{[2
]}

Coleman, Morton ^{[3
]}

Smith, Sonali M. ^{[4
]}

Venugopal, Parameswaran ^{[5
]}

Martin, Peter ^{[6
]}

Wood, Andrew ^{[7
]}

Miller, Kara ^{[8
]}

Christian, Beth ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Norton Canc Inst, Louisville, KY USA

[3] Weill Cornell Med, Clin Res Alliance, New York, NY USA

[4] Univ Chicago, Med Ctr, Chicago, IL USA

[5] Rush Univ, Med Ctr, Chicago, IL USA

[6] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA

[7] AstraZeneca, Cambridge, England

[8] AstraZeneca, South San Francisco, CA USA

[9] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 06期

关键词：

B-cell lymphoma; Bruton tyrosine kinase; non-Hodgkin lymphoma; TYROSINE KINASE INHIBITOR; B-CELLS; IBRUTINIB; ACP-196;

D O I：

10.1111/bjh.19787

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.

引用

页码：2248 / 2253

页数：6

共 50 条

[41] A phase III open label randomized study to compare the efficacy of lenalidomide-rituximab vs bendamustine-rituximab in treatment naive follicular lymphoma.
Paikaray, Susanta Kumar
Gogia, Ajay
Kumar, Lalit
Sharma, Atul
Biswas, Ahitagni
Sharma, Mehar C.
Thulker, Sanjay
Kumar, Rakesh
Vishnubhatla, Sreenivas
Mallick, Saumyaranjan
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma:: Outcomes of an expanded access program
Jaenne, Pasi A.
Wozniak, Antoinette J.
Belani, Chandra P.
Keohan, Mary-Louise
Ross, Helen J.
Polikoff, Jonathan A.
Mintzer, David M.
Taylor, Loretta
Ashland, Joseph
Ye, Zhishen
Monberg, Matthew J.
Obasaju, Coleman K.
CLINICAL LUNG CANCER, 2005, 7 (01) : 40 - 46
[43] Results of a nonrandomized, open-label, phase II study of combined gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
Garbo, Lawrence E.
Flynn, Patrick J.
MacRae, Margaret A.
Rauch, Mary A.
Wang, Yunfei
Kolibaba, Kathryn S.
BLOOD, 2007, 110 (11) : 183B - 183B
[44] Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study
Kiely, PDW
Johnson, DM
RHEUMATOLOGY, 2002, 41 (06) : 631 - 637
[45] A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
Awan, Farrukh T.
Hillmen, Peter
Hellmann, Andrzej
Robak, Tadeusz
Hughes, Steven G.
Trone, Denise
Shannon, Megan
Flinn, Ian W.
Byrd, John C.
BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (04) : 466 - 477
[46] An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy
Chaudhry, Vinay
Cornblath, David R.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2010, 15 (03) : 196 - 201
[47] Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Gopal, Ajay K.
Schuster, Stephen J.
Fowler, Nathan H.
Trotman, Judith
Hess, Georg
Hou, Jing-Zhou
Yacoub, Abdulraheem
Lill, Michael
Martin, Peter
Vitolo, Umberto
Spencer, Andrew
Radford, John
Jurczak, Wojciech
Morton, James
Caballero, Dolores
Deshpande, Sanjay
Gartenberg, Gary J.
Wang, Shean-Sheng
Damle, Rajendra N.
Schaffer, Michael
Balasubramanian, Sriram
Vermeulen, Jessica
Cheson, Bruce D.
Salles, Gilles
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (23) : 2405 - +
[48] Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study
Rummel, Mathias J.
Kim, Tae Min
Aversa, Franco
Brugger, Wolfram
Capochiani, Enrico
Plenteda, Caterina
Re, Francesca
Task, Peter
McIntyre, Christine
Meier, Oliver
Osborne, Stuart
Smith, Rodney
Grigg, Andrew
BLOOD, 2017, 130
[49] An Open-Label Trial Of Rituximab Therapy In Pulmonary Alveolar Proteinosis
Marshall, I.
Malur, A.
Barna, B.
Huizar, I.
Dalrymple, H.
Karnekar, R.
Kavuru, M. S.
Thomassen, M. J.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
[50] An open-label trial of rituximab therapy in pulmonary alveolar proteinosis
Kavuru, M. S.
Malur, A.
Marshall, I.
Barna, B. P.
Meziane, M.
Huizar, I.
Dalrymple, H.
Karnekar, R.
Thomassen, M. J.
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (06) : 1361 - 1367

← 1 2 3 4 5 →